JP2003515601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003515601A5 JP2003515601A5 JP2001541898A JP2001541898A JP2003515601A5 JP 2003515601 A5 JP2003515601 A5 JP 2003515601A5 JP 2001541898 A JP2001541898 A JP 2001541898A JP 2001541898 A JP2001541898 A JP 2001541898A JP 2003515601 A5 JP2003515601 A5 JP 2003515601A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- carbon atoms
- independently
- alkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 34
- 150000003839 salts Chemical class 0.000 description 33
- 125000004432 carbon atom Chemical group C* 0.000 description 26
- 125000000217 alkyl group Chemical group 0.000 description 16
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 125000000304 alkynyl group Chemical group 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 125000004475 heteroaralkyl group Chemical group 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 229960005520 bryostatin Drugs 0.000 description 4
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- -1 hydroxyl compound Chemical class 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16818199P | 1999-11-30 | 1999-11-30 | |
| US60/168,181 | 1999-11-30 | ||
| PCT/US2000/032896 WO2001040214A1 (en) | 1999-11-30 | 2000-11-30 | Bryostatin analogues, synthetic methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003515601A JP2003515601A (ja) | 2003-05-07 |
| JP2003515601A5 true JP2003515601A5 (enExample) | 2008-01-24 |
Family
ID=22610449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541898A Pending JP2003515601A (ja) | 1999-11-30 | 2000-11-30 | ブリオスタチンアナログ、合成方法および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6624189B2 (enExample) |
| EP (1) | EP1233956A4 (enExample) |
| JP (1) | JP2003515601A (enExample) |
| AU (1) | AU784589B2 (enExample) |
| CA (1) | CA2393026A1 (enExample) |
| WO (1) | WO2001040214A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7256286B2 (en) * | 1999-11-30 | 2007-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US20080004332A1 (en) * | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| PA8580301A1 (es) * | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| US7232842B2 (en) * | 2003-01-10 | 2007-06-19 | Board Of Trustees Of The Leland Stanford Junior University | Kinase inhibitors and associated pharmaceutical compositions and methods of use |
| EP1603557A4 (en) * | 2003-02-20 | 2008-05-21 | Univ Texas | SYNTHESIS OF PELORUSIDE A AND ITS ANALOGUE FOR USE AS ANTITUMORAL AGENTS |
| TW201207390A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Method for screening agent for antidepressant activity |
| US20070026488A1 (en) * | 2005-07-27 | 2007-02-01 | Targett Nancy M | Biosynthesis of bryostatins by polyketide synthases (PKS) |
| US20070054890A1 (en) | 2005-07-29 | 2007-03-08 | Alkon Daniel L | Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning |
| JP4710698B2 (ja) * | 2006-04-10 | 2011-06-29 | 宇部興産株式会社 | シリルエーテル基を有するβ−ジケトン化合物の製造法 |
| EP2762136A1 (en) | 2006-07-28 | 2014-08-06 | Blanchette Rockefeller Neurosciences, Institute | Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory |
| US20080058396A1 (en) * | 2006-07-28 | 2008-03-06 | Alkon Daniel L | Methods of stimulating cellular growth, synaptic remodelling and consolidation of long-term memory |
| CN101848726A (zh) * | 2007-02-09 | 2010-09-29 | 布朗歇特洛克菲勒神经科学研究所 | 苔藓抑素、苔藓抑素类似物和其它相关物质对头部创伤引起的记忆缺陷和脑损伤的疗效 |
| US8497385B2 (en) * | 2007-08-31 | 2013-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| WO2009052507A1 (en) * | 2007-10-19 | 2009-04-23 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
| EP2590642B1 (en) | 2010-07-08 | 2018-03-14 | Daniel L. Alkon | Pkc activators and anticoagulant in regimen for treating stroke |
| JP6062362B2 (ja) | 2010-08-19 | 2017-01-18 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | Ｐｋｃ活性化剤を使用した、異常な樹状突起棘に関連した認知障害の治療 |
| WO2013071281A1 (en) | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla and methods of treatment using the same |
| WO2013071282A1 (en) | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Pkc activators and combinations thereof |
| US9034347B2 (en) | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
| US9816066B2 (en) | 2012-04-24 | 2017-11-14 | The Regents Of The University Of California | Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters |
| CN105008342B (zh) * | 2012-11-27 | 2018-10-19 | 阿菲欧斯公司 | 苔藓素组合物、其制备方法和用途 |
| JP6579956B2 (ja) | 2012-11-28 | 2019-09-25 | アフィオス コーポレーション | 神経変性疾患および他の疾患の治療のための併用治療薬および方法 |
| WO2014145316A1 (en) | 2013-03-15 | 2014-09-18 | Alkon Daniel L | Methods for identifying neuroprotective pkc activators |
| US9724328B2 (en) | 2014-04-18 | 2017-08-08 | Icahn School Of Medicine At Mount Sinai | Methods and compositions for treatment of lipid storage disorders |
| US20180217163A1 (en) | 2015-05-11 | 2018-08-02 | Daniel L. Alkon | Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele |
| US20180256537A1 (en) | 2015-09-23 | 2018-09-13 | Tapan K. Khan | Methods for survival and rejuvenation of dermal fibroblasts using pkc activators |
| WO2017062924A1 (en) | 2015-10-08 | 2017-04-13 | Alkon Daniel L | Dosing regimens of pkc activators |
| CN109982695A (zh) | 2016-08-18 | 2019-07-05 | 国立大学法人奈良先端科学技术大学院大学 | 免疫调节剂 |
| JP7148147B2 (ja) | 2016-10-05 | 2022-10-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ブリオスタチン化合物およびその調製方法 |
| CN110869046B (zh) | 2017-03-31 | 2025-02-25 | 塞勒克提斯公司 | 通用型抗cd22嵌合抗原受体工程化的免疫细胞 |
| WO2018187647A1 (en) | 2017-04-06 | 2018-10-11 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of neurological diseases, disorders, or conditions |
| US20190350898A1 (en) | 2018-05-18 | 2019-11-21 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of alzheimer's disease |
| US20220133687A1 (en) * | 2020-11-02 | 2022-05-05 | Synaptogenix, Inc. | Methods of treating and preventing neurodegenerative diseases with hgf activating compounds |
| AU2021386370A1 (en) | 2020-11-24 | 2023-06-22 | Lyell Immunopharma, Inc. | Methods for making, compositions comprising, and methods of using rejuvenated t cells |
| CN113773256B (zh) * | 2021-09-16 | 2022-11-18 | 精华制药集团南通有限公司 | 一种琥布宗的合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560774A (en) * | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
| US4611066A (en) * | 1984-08-10 | 1986-09-09 | Arizona State University | Bryostatins 4 to 8 |
| US5891870A (en) | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators Q |
| US4833257A (en) * | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
| WO1997034598A1 (en) | 1996-03-20 | 1997-09-25 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of treating cancer using c-26 modified bryostatin |
-
2000
- 2000-11-30 CA CA002393026A patent/CA2393026A1/en not_active Abandoned
- 2000-11-30 AU AU19440/01A patent/AU784589B2/en not_active Ceased
- 2000-11-30 EP EP00982401A patent/EP1233956A4/en not_active Withdrawn
- 2000-11-30 US US09/728,929 patent/US6624189B2/en not_active Expired - Lifetime
- 2000-11-30 WO PCT/US2000/032896 patent/WO2001040214A1/en not_active Ceased
- 2000-11-30 JP JP2001541898A patent/JP2003515601A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2198162C2 (ru) | Производное 2-аминопропан-1,3-диола, его фармацевтическое применение и промежуточные продукты для их синтеза | |
| WO2009009501A4 (en) | Non-basic melanin concentrating hormone receptor-1 antagonists and methods | |
| JP2006507220A5 (enExample) | ||
| JP2002539181A5 (enExample) | ||
| JP2005533013A5 (enExample) | ||
| JPH0776174B2 (ja) | 医薬組成物および処置法 | |
| WO2005000353A1 (ja) | 血清コレステロール低下剤或はアテローム性動脈硬化症の予防又は治療剤 | |
| CA2434028A1 (en) | Amino ceramide-like compounds and therapeutic methods of use | |
| JP2022541545A5 (enExample) | ||
| JP2004531478A5 (enExample) | ||
| US4599355A (en) | Treatment of sleep disorders | |
| CN1466465A (zh) | 肥胖或脂肪肝的预防或治疗药物 | |
| JPH0273016A (ja) | ５‐ヘテロアリールまたは５‐アリール置換イミダゾ［２，１―ａ］イソキノリンの使用 | |
| EP2139463B1 (en) | Anti-infective agents | |
| JP2005532397A5 (enExample) | ||
| CA2491612A1 (en) | 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| US4647580A (en) | Treatment of Alzheimer's disease | |
| CA2523253A1 (en) | Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists | |
| RU2001104880A (ru) | Пиперазиновые производные, обладающие антидиабетической активностью, способы их получения и содержащие их композиции | |
| CZ20021435A3 (cs) | Pro-léčiva 6-methoxy-2-naftyloctové kyseliny | |
| US8153687B2 (en) | Gallium complexes with polyalcohols and methods of use | |
| US8389732B2 (en) | Synthesis and regioselective substitution of 6-halo- and 6-alkoxy nicotine derivatives | |
| EP0623346A1 (en) | Inhibitor for metastasis of malignant tumor | |
| JP2002520413A5 (enExample) | ||
| JP2565543B2 (ja) | イソオキサゾール化合物およびその用途 |